Oligonucleotides

Chemical modifications for therapeutic aptamers

Chemical modifications for therapeutic aptamers

H Rose, A Ansari, E A Hassan et al

For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

Unveiling the potential of RNA-targeting therapies

Unveiling the potential of RNA-targeting therapies

Rabia Khan, Loïc Roux

05 December 2024

Tackling the key challenges for therapeutic oligonucleotide manufacture: cost, scale, and sustainability

Tackling the key challenges for therapeutic oligonucleotide manufacture: cost, scale, and sustainability

26 November 2024

Bridging the translational gap: humanized liver models as predictive tools for RNA therapeutic success

Bridging the translational gap: humanized liver models as predictive tools for RNA therapeutic success

Matthew Baginski, Sara Donnelly

21 November 2024

Innovator Insight

Advancing treatment of genetic diseases through engineered tRNA therapeutics

Advancing treatment of genetic diseases through engineered tRNA therapeutics

William Kiesman

24 September 2024

Delivering on the next generation of oligo therapies depends on overcoming, not ignoring, that sequence and chemistry are separable, but not independent

Delivering on the next generation of oligo therapies depends on overcoming, not ignoring, that sequence and chemistry are separable, but not independent

Harnessing the potential of AI/ML to expand the horizons of the oligonucleotide therapeutics field

Harnessing the potential of AI/ML to expand the horizons of the oligonucleotide therapeutics field

Arijit Bhowmick

Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing

Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing

1
2
>
>>

Mastering IP-RPLC-MS for high-throughput & high-resolution oligonucleotide impurity profiling

Mastering IP-RPLC-MS for high-throughput & high-resolution oligonucleotide impurity profiling

Sebastiaan Eeltink, Quang-Dong Bui

A scalable purification strategy for removal of dsRNA byproducts following IVT RNA production

A scalable purification strategy for removal of dsRNA byproducts following IVT RNA production

Nathaniel Clark

mRNA characterization - from 5’ cap to poly (A): what IPRP-LC–MS can tell you

mRNA characterization - from 5’ cap to poly (A): what IPRP-LC–MS can tell you

Roxana Eggleston

06 November 2024